Burden of atopic dermatitis in infants/preschoolers from EPI-CARE: an international study
At the SPD 2022 47th Annual Meeting in Indianapolis, Indiana, a poster session on atopic dermatitis severity and outcomes in young children from 5 regions around the world.
Stephan Weidinger, MD, Eric L. Simpson, MD, PhD; and Jonathan I. Silverberg, MD, PhD, et al, presented a poster on an EPI-CARE cross-sectional, web-based study conducted between September 2018 and December 2019 to examine varying conditions of atopic dermatitis severity and outcomes in infants and preschoolers aged 6 months to less than 6 years in 5 regions: North America, Latin America, Europe, the Middle East/Eurasia, and East Asia.
Parents and guardians were asked to answer questions related to the impact of atopic dermatitis (AD), while preschoolers aged 4 to 6 years were asked questions related to the impact of AD on their own quality of life.
Parents were asked to assess their child’s AD condition as mild, moderate, or severe, and outcomes were stratified by geographic region; AD severity; worst itch/skin pain; sleep disturbance over 24-hour periods; eczema-related hospitalizations over the prior 12 months; and frequency and typical duration of flares over the prior month.
Results showed that of 1489 infants/preschoolers aged less than 6 years, the majority (61.6%) had mild disease, with the rest of the children with moderate to severe disease. The children with moderate or severe AD had the worst itch, skin pain, and sleep disturbances over the prior 24 hours, and the majorityof those with severe AD (54.1%) were hospitalized over the prior 12 months.
More than half of severe AD children also had more than 2 flares over the prior month, compared with smaller proportions of moderate and mild infants and preschoolers.
The investigators concluded, that across all regions, infants and preschoolers with AD experience a considerable burden that can include atopic comorbidities, pruritus, sleep loss, hospitalization, frequent prolong flares, and school attendance, results which should be looked at and considered carefully when health care providers screen and treat this population for AD.
Reference
Weidinger, MD, Simpson EL, Silverberg JI, et al. Burden of atopic dermatitis in infants/preschoolers from EPI-CARE: an international study. SPD 2022 47th Annual Meeting. July 7, 2022. Indianapolis, Indiana.
Recognize & Refer: Hemangiomas in pediatrics
July 17th 2019Contemporary Pediatrics sits down exclusively with Sheila Fallon Friedlander, MD, a professor dermatology and pediatrics, to discuss the one key condition for which she believes community pediatricians should be especially aware-hemangiomas.
Worsening severity of AD in children associated with increased comorbidity onset risk
November 27th 2023Of patients in the atopic dermatitis (AD) cohort, 36.6% developed at least 1 comorbidity amid follow-up compared to 28.5% in the non-AD reference cohort, investigators of a Sweden, nationwide, population-based cohort study found.
IDP-126 topical gel approved by FDA to treat acne in patients 12 years and up
October 21st 2023The topical gel is the first and only FDA-approved triple-combination, fixed-dose topical treatment for acne, and is set to be available in the first quarter of 2024, according to Bausch Health Companies Inc.
A 13-year-old girl with well-demarcated rash on back and chest
October 19th 2023A healthy 13-year-old girl presented with a 1-month history of an asymptomatic, well-demarcated rash on her back and upper chest. The eruption consisted of discrete, dark brown papules that coalesced into large, flat-topped plaques with mild superficial scale and accentuation of skin markings. What's the diagnosis?
Tapinarof cream 1% reduces itch as early as 24 hours after application for pediatric AD
October 13th 2023A rapid reduction in pruritis as early as 24 hours after first application was announced as new positive data from a pair of identical, phase 3 studies of tapinarof cream 1% in children as young as 2 years and adults with atopic dermatitis (AD).
